Lord, Abbett & Co
DNLI icon

Lord, Abbett & Co’s Denali Therapeutics DNLI Stock Holding History

Lord, Abbett & Co’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-147,386
Closed -$5.28M – 663
2020
Q3 		$5.28M Sell
147,386
-9,008
-6% -$271K 0.02% 561
2020
Q2 		$3.78M Sell
156,394
-83,108
-35% -$1.95M 0.01% 592
2020
Q1 		$4.19M Buy
239,502
+6,860
+3% +$143K 0.02% 556
2019
Q4 		$4.05M Sell
232,642
-937,242
-80% -$15.6M 0.01% 611
2019
Q3 		$17.9M Sell
1,169,884
-576,042
-33% -$11M 0.06% 427
2019
Q2 		$36.2M Buy
1,745,926
+89,677
+5% +$2.01M 0.12% 298
2019
Q1 		$38.5M Buy
1,656,249
+217,641
+15% +$4.55M 0.13% 258
2018
Q4 		$29.7M Buy
1,438,608
+313,153
+28% +$5.68M 0.11% 290
2018
Q3 		$24.5M Buy
1,125,455
+761,599
+209% +$12.6M 0.07% 430
2018
Q2 		$5.55M Buy
363,856
+79,244
+28% +$1.49M 0.02% 725
2018
Q1 		$5.6M Buy
+284,612
New +$5.85M 0.02% 707

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Lord, Abbett & Co's DNLI Position: Q4 2020 in Review

Lord, Abbett & Co sold out of Denali Therapeutics (DNLI) in Q4 2020, closing a stake of 147,386 shares — an estimated $5.28M sold.

Lord, Abbett & Co first reported a position in DNLI in Q1 2018 and held it in 11 quarters. The position peaked at $38.5M in Q1 2019. 205 funds tracked by Wall St. Rank hold DNLI as of Q4 2020.

  • Lord, Abbett & Co reported no remaining Denali Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Lord, Abbett & Co sold 147,386 Denali Therapeutics shares in Q4 2020, an estimated $5.28M.
  • Lord, Abbett & Co first reported a position in Denali Therapeutics in Q1 2018 and held it in 11 quarters.
  • Lord, Abbett & Co's Denali Therapeutics position peaked at $38.5M in Q1 2019.
  • 205 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2020.

Based on Lord, Abbett & Co's 13F filing for Q4 2020, filed 9 Feb 2021.